Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias.
Alzheimers Dement
; 12(11): 1116-1124, 2016 11.
Article
in En
| MEDLINE
| ID: mdl-26892233
ABSTRACT
INTRODUCTION:
Aggregation of tau is a hallmark of many neurodegenerative diseases, and tau imaging with positron emission tomography (PET) may allow early diagnosis and treatment monitoring. We assessed binding of the PET tracer [18F]AV-1451 in a range of dementias.METHODS:
Phosphorimaging was used to quantify binding to postmortem brain tissue from 33 patients with different, histopathologically characterized, neurodegenerative dementias.RESULTS:
[18F]AV-1451 showed high specific binding in cases with Alzheimer's disease (AD), moderate binding in Pick's disease and frontotemporal dementia with parkinsonism-17, and low but displaceable binding in corticobasal degeneration, progressive supranuclear palsy, non-tau proteinopathies, and in controls without pathology. Tracer binding did not correlate with tau load within disease groups.DISCUSSION:
[18F]AV-1451 binds to tau in AD, and some other tauopathies. However, evidence for a non-tau binding site and lack of correlation between tracer binding and antibody staining suggest that reliable quantification of tau load with this tracer is problematic.Key words
Full text:
1
Database:
MEDLINE
Main subject:
Brain
/
Carbolines
/
Radiopharmaceuticals
/
Neurodegenerative Diseases
/
Dementia
/
Positron-Emission Tomography
Type of study:
Screening_studies
Limits:
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Alzheimers Dement
Year:
2016
Type:
Article
Affiliation country:
United kingdom